Secukinumab + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rotator Cuff Tendinopathy
Conditions
Rotator Cuff Tendinopathy
Trial Timeline
Aug 10, 2023 → Dec 13, 2024
NCT ID
NCT05722522About Secukinumab + Placebo
Secukinumab + Placebo is a phase 3 stage product being developed by Novartis for Rotator Cuff Tendinopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT05722522. Target conditions include Rotator Cuff Tendinopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05722522 | Phase 3 | Terminated |
| NCT05758415 | Phase 3 | Terminated |
| NCT04737330 | Phase 3 | Terminated |
| NCT04732117 | Phase 3 | Completed |
| NCT04181762 | Phase 3 | Terminated |
| NCT04156620 | Phase 3 | Completed |
| NCT03713632 | Phase 3 | Completed |
| NCT03713619 | Phase 3 | Completed |
| NCT03055494 | Approved | Completed |
| NCT02896127 | Phase 3 | Completed |
| NCT02696031 | Phase 3 | Completed |
| NCT02599129 | Phase 2 | Terminated |
| NCT02594098 | Phase 2 | Completed |
| NCT02362789 | Phase 3 | Completed |
| NCT01989468 | Phase 3 | Completed |
| NCT02044848 | Phase 2 | Terminated |
| NCT01892436 | Phase 3 | Completed |
| NCT01807520 | Phase 3 | Completed |
| NCT01537432 | Phase 2 | Completed |
Competing Products
5 competing products in Rotator Cuff Tendinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |
| BMP-655/ACS+Standard of care or Standard of care + BMP-655/ACS+Standard of care or Standard of care + BMP-655/ACS+Standard of care or Standard of care | Pfizer | Phase 1 | 32 |
| BMP-655/ACS or Standard of Care + BMP-655/ACS or Standard of Care + BMP-655/ACS or Standard of Care | Pfizer | Phase 1 | 32 |
| Pregabalin | Viatris | Approved | 82 |
| Single Injection of Local Anesthetic | Baxter | Phase 1 | 30 |